Pulmonary Embolism Drugs Market

Pulmonary Embolism Drugs Market Segmentation by Drug Class (Thrombolytics, Heparins, Thrombin Inhibitors, and Others); by Distribution Channel (Hospital Pharmacy, Drug Store, Online Pharmacy, and Others) – Global Demand Analysis & Opportunity Outlook 2030

Buy Now
Report ID: 3400 | Published On: Feb 08, 2023

Preview Analysis

Request Insights
Despite Inflation & Recession News, Businesses Across the Globe Expected to Do Better in 2023

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.


In The News


Global Pulmonary Embolism Drugs Market Highlights over 2022 – 2030

The global pulmonary embolism drugs market is estimated to grow at a robust CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing prevalence of pulmonary embolism. This is a condition, where a blood clot occurs in the lungs, which often is formed in other body parts and moves to the lungs through bloodstream. This limits the flow of blood to the lungs, which reduces the flow of oxygen in the body, and increases blood pressure. Pulmonary embolism drugs are used to dissolve the clots or inhibit their formation. Patients undergoing chemotherapy, or people with family history of this disease are at most risk, which is estimated to boost the demand for the drugs. Increasing patient pool of cancer is estimated to fuel the growth of the market. According to the World Health Organization, cancer caused nearly 10 million deaths in 2020. Moreover, increasing government investment to improve the public healthcare system in developing and developed countries, is further anticipated to boost the market growth.  

Pulmonary Embolism Drugs Market Graph

Get more information on this reportDownload Sample PDF

The market is segmented by drug class into thrombolytics, heparins, thrombin inhibitors, and others out of which, the heparins segment is anticipated to hold the largest share in the global pulmonary embolism drugs market over the forecast period owing to the anticoagulant properties of heparins, that are used to dissolve the blood clot. On the basis of distribution channel, the hospital pharmacies segment is anticipated to garner the highest market revenue over the forecast period, owing to the easy accessibility of drugs to the patients admitted in hospitals.


Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita Graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.


Global Pulmonary Embolism Drugs Market Regional Synopsis

On the basis of geographical analysis, the global pulmonary embolism drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America region is estimated to witness noteworthy growth over the forecast period on the back of high healthcare expenditure in the region. According to a report by the World Health Organization (WHO), as of 2018, the per capita healthcare expenditure of North America valued USD 10,050.279. Moreover, presence of major pharmaceutical companies in the region is estimated to boost the market growth.

The market in the Asia Pacific region is estimated to gain significant share in the market over the forecast period, owing to the high prevalence of cancer in the region, along with high geriatric population, both of which are a major cause for pulmonary embolism.

Pulmonary Embolism Drugs Market Share Graph

Get more information on this reportDownload Sample PDF

The global pulmonary embolism drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis


Pulmonary Embolism Drugs Market Graph
Get more information on this report: Request Sample PDF

Market Segmentation

Our in-depth analysis of the global pulmonary embolism drugs market includes the following segments:

By Drug Class

  • Thrombolytics
  • Heparins
  • Thrombin Inhibitors 
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Drug Store
  • Online Pharmacy
  • Others

Growth Drivers

  • Increasing Prevalence of Pulmonary Embolism
  • Rising R&D Activities for New Drugs

Challenges

  • Side Effects of these Drugs


Healthcare Expenditure per Capita Graph
Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Market

    • Janssen Pharmaceuticals, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
    • Novartis AG
    • Pfizer Inc.
    • Sanofi-aventis Groupe
    • Abbott Laboratories
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Daiichi Sankyo Company, Limited
    • Siemens Healthcare GmbH
    • Baxter International, Inc.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the pulmonary embolism drugs market?

Ans: Increasing prevalence of pulmonary embolism and deadly nature of this disease are estimated to boost the market growth.

2) What would be the CAGR of pulmonary embolism drugs market over the forecast period?

Ans: The market is anticipated to attain a robust CAGR over the forecast period, i.e., 2022 – 2030.

3) What are the challenges affecting the pulmonary embolism drugs market growth?

Ans: Side effects of the drugs are estimated to hamper the market growth.

4) Which region will provide more business opportunities for growth of pulmonary embolism drugs market in future?

Ans: the market in the North America region is estimated to provide most growth opportunities over the forecast period, owing to the presence of major pharmaceutical companies in the region.

5) Who are the major players dominating the pulmonary embolism drugs market?

Ans: The major players in the market are Novartis AG, Pfizer Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the pulmonary embolism drugs market?

Ans: The market is segmented by drug class, distribution channel, and by region.

8) Which sub-segment captures the largest market size in the drug class segment in the pulmonary embolism drugs market?

Ans: The heparins segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Submit RFP    Buy Now Download Research Report Sample